A 40-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the safety and efficacy of ABT-494 in adult participants with moderate to severe atopic dermatitis. The participants will be randomized in a 1:1:1:1 ratio to one of four treatment groups.
A Phase III extension trial for patients ages 6 months to 18 years of age who have previously participated in a clinical trial for dupilumab.
Dermira protocol DRM06-AD01: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial To Evaluate The Efficacy And Safety Of Lebrikizumab In Patients With Moderate-To-Severe Atopic Dermatitis-CURRENTLY ENROLLING
A Phase II clinical trial investigating a biologic IL-13 inhibitor for patients 18 years of age or older with moderate to severe atopic dermatitis.